New pill aims to revive fetal hemoglobin and calm sickle cell crisis

NCT ID NCT06546670

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This early-stage study tests a new drug, ITU512, in healthy volunteers and people with sickle cell disease. The goal is to see if it safely boosts fetal hemoglobin, a natural protein that can reduce painful sickle cell complications. The trial first checks safety and dosing in healthy adults, then moves to patients to measure effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Boston Childrens Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Lifespan

    RECRUITING

    Providence, Rhode Island, 02903, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Quotient Sciences Sea View

    COMPLETED

    Miami, Florida, 33126, United States

  • University of Alabama Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.